Lv6
2310 积分 2023-06-12 加入
Myelodysplastic Syndromes
3个月前
已完结
Clinical effectiveness and safety of erythropoietin‐stimulating agents for the treatment of low‐ and intermediate‐1−risk myelodysplastic syndrome: a systematic literature review
3个月前
已完结
Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology
3个月前
已关闭
Diagnosis and Treatment of Myelodysplastic Syndromes
4个月前
已完结
Real‐Time, Tissue‐Adaptive Photoacoustic Thermometry for Precision Endoscopic Thermal Therapy
4个月前
已完结
Optimal Rituximab Monotherapy in Splenic Marginal Zone Lymphoma (SMZL): A Case Report and Brief Review
7个月前
已完结
Long-Term Experience with Luspatercept in Relapsed/Refractory Myelodysplastic Neoplasms: A Chinese Real-World Study
9个月前
已完结
Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial
11个月前
已完结
Lower-dose post-transplant cyclophosphamide in haploidentical hematopoietic cell transplantation
1年前
已完结
Favorable outcomes in MDS and oligoblastic AML-MR after reduced-intensity conditioning allogeneic bone marrow transplantation with post-transplantation cyclophosphamide
1年前
已完结
皖公网安备34019202002308
